• Burns McClellan is a pioneer in life sciences investor relations and strategic communications.

    Since 1988, Burns McClellan has served as a strategic investor relations and communications partner to the global life sciences industry. As the nation’s oldest independent life sciences investor relations consultancy, we advise companies developing innovative therapeutics, medical devices and diagnostics. Burns McClellan maintains an extensive network of institutional investors, healthcare-focused funds, sell-side analysts, investment bankers, venture capital firms and other influential market participants, helping clients build visibility, credibility and engagement within the investment community.

  • We bridge the gap between scientific innovation and the capital markets.

    Our professionals bring expertise spanning science, clinical development, regulatory affairs, equity research, institutional investing, investment banking, management consulting and corporate communications. We understand the complexities of therapeutic discovery and clinical development—and how to translate those milestones into a compelling investment thesis that resonates with investors, analysts and other key stakeholders.

  • We believe in strategy before tactics.

    We work closely with management teams to develop communications and investor relations strategies aligned with corporate, clinical and financial objectives. We believe that thoughtful planning, consistent execution and proactive stakeholder engagement are critical to building long-term credibility and creating shareholder value. We then leverage decades of experience to execute programs that support our clients’ strategic goals.

  • We support companies through every stage of growth and development.

    Working alongside management teams, legal counsel, regulatory advisors and other stakeholders, Burns McClellan supports companies through all stages of corporate, clinical and financial development. From private financings and IPO preparation to commercialization and long-term growth, we help clients communicate effectively with investors, analysts, media and other key constituencies. We are proud to partner with organizations advancing healthcare through innovative science and transformative technologies.

35+ Years Dedicated to Life Sciences 

History

Founded in 1988 by Lisa Burns, Burns McClellan is the nation’s oldest independent investor relations and strategic communications consultancy dedicated exclusively to the life sciences industry.

Burns McClellan has advised companies developing breakthrough therapies and technologies across diverse therapeutic areas, helping management teams communicate complex scientific, clinical, regulatory and corporate milestones to investors and other key stakeholders.

The Firm has represented more than 400 innovative life sciences companies across all stages of corporate development, from early-stage financing and IPO preparation through commercialization and long-term growth.

Over nearly four decades, Burns McClellan has supported companies through critical inflection points including private financings, IPOs, follow-on offerings, clinical milestones, strategic partnerships, product launches and commercialization.

Sector Expertise

Burns McClellan helps private and public life sciences companies articulate a differentiated investment thesis, engage effectively with investors and analysts, and communicate their value to key stakeholders.

Our team brings experience across science, clinical development, regulatory affairs, equity research, institutional investing, investment banking, management consulting, and corporate communications, providing a multidisciplinary perspective to support our clients' strategic objectives.

We work with companies that:

  • Specialize in key life sciences sectors, with a focus on innovative therapeutics, including diagnostics and medical devices.

  • Focus in diverse therapeutic areas including oncology, orphan/genetic diseases, ophthalmology, cardiovascular disease, CNS diseases and disorders, immunology, and infectious diseases.

  • Leverage a variety of technology platforms including small molecules, biologics, cell therapies, gene therapies and nucleic acid platforms, transplantation technologies, drug delivery technologies, and preventive and therapeutic vaccines.

Our team understands that every therapeutic area presents distinct scientific, clinical, regulatory and market dynamics. We leverage deep sector expertise to help clients develop a compelling investment thesis, communicate key differentiators, and position their companies effectively with investors and other stakeholders.